SCHEMBL371648

SCHEMBL371648

COc1cc2nccc(Oc3ccc(NC(=O)CC(=O)Nc4ccc(F)cc4)cc3)c2cc1OC

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRA P16234 15/20 0.84
KDR P35968 15/20 0.84
MET P08581 4/20 0.78
AURKA O14965 1/20 0.75
RIPK2 O43353 1/20 0.75
ABCB11 O95342 1/20 0.75
ABL1 P00519 1/20 0.75
EGFR P00533 1/20 0.75
ERBB2 P04626 1/20 0.75
NTRK1 P04629 1/20 0.75
LCK P06239 1/20 0.75
PGR P06401 1/20 0.75
LYN P07948 1/20 0.75
RET P07949 1/20 0.75
CHRM2 P08172 1/20 0.75
HCK P08631 1/20 0.75
ADRA2A P08913 1/20 0.75
ADORA3 P0DMS8 1/20 0.75
KIT P10721 1/20 0.75
CHRM1 P11229 1/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24142383 0.93 PDGFRA (0.79) PDGFRAKDRMETAURKARIPK2
SCHEMBL5824367 0.93 PDGFRA (0.79) PDGFRAKDRMETAURKARIPK2
SCHEMBL7479859 0.91 PDGFRA (1.00) PDGFRAKDRMETAURKARIPK2
SCHEMBL1878918 0.91 KDR (0.83) PDGFRAKDRMETAURKARIPK2
SCHEMBL1877070 0.90 PDGFRA (0.84) PDGFRAKDRMETKITAXL
SCHEMBL1880008 0.89 KDR (0.84) PDGFRAKDRMETAURKALCK
SCHEMBL1878723 0.89 PDGFRA (0.92) PDGFRAKDRMETAURKARIPK2
SCHEMBL28708722 0.89 PDGFRA (0.74) PDGFRAKDRMETKITAXL
SCHEMBL29438545 0.89 PDGFRA (0.74) PDGFRAKDRMETKITAXL
SCHEMBL23835028 0.89 PDGFRA (0.74) PDGFRAKDRMETKITAXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. 2021-08-19 US claimed
US-20200331860-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2020-10-22 US claimed
EP-2101759-B1 METHODS OF USING MEK INHIBITORS EXELIXIS INC (US) 2018-10-10 EP claimed
US-20170355678-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2017-12-14 US claimed
US-20150376133-A1 C-Met Modulators and Methods of Use EXELIXIS, INC. 2015-12-31 US claimed
EP-2101759-A1 METHODS OF USING MEK INHIBITORS Exelixis, Inc. (US) 2009-09-23 EP claimed
EP-2088141-A2 Quinoline derivatives and quinazoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same Kirin Pharma Kabushiki Kaisha (JP) 2009-08-12 EP claimed
US-20080312221-A1 QUINOLINE DERIVATIVE AND QUINAZOLINE DERIVATIVE INHIBITING SELF-PHOSPHORYLATION OF HEPATOCYTUS PROLIFERATOR RECEPTOR, AND MEDICINAL COMPOSITION CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2008-12-18 US claimed
US-7425564-B2 Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus prolifertor receptor and medicinal composition containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2008-09-16 US claimed
WO-2008076415-A1 METHODS OF USING MEK INHIBITORS EXELIXIS, INC. (US) 2008-06-26 WO claimed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 US claimed
US-20040242603-A1 Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus proliferator receptor and medicinal composition containing the same KIRIN HOLDINGS KABUSHIKI KAISHA (JP) 2004-12-02 US claimed
EP-1411046-A1 QUINOLINE DERIVATIVE AND QUINAZOLINE DERIVATIVE INHIBITING SELF−PHOSPHORYLATION OF HEPATOCYTUS PROLIFERATOR RECEPTOR, AND MEDICINAL COMPOSITION CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2004-04-21 EP claimed
EP-3329918-B1 C-MET MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2022-05-25 EP disclosed
US-11124482-B2 C-met modulators and methods of use EXELIXIS, INC. (US) 2021-09-21 US disclosed
US-11124482-B2 C-met modulators and methods of use EXELIXIS, INC. (US) 2021-09-21 US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 US disclosed
US-20040242603-A1 Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus proliferator receptor and medicinal composition containing the same KIRIN HOLDINGS KABUSHIKI KAISHA (JP) 2004-12-02 US disclosed
EP-1411046-A1 QUINOLINE DERIVATIVE AND QUINAZOLINE DERIVATIVE INHIBITING SELF−PHOSPHORYLATION OF HEPATOCYTUS PROLIFERATOR RECEPTOR, AND MEDICINAL COMPOSITION CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2004-04-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200331860-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET PDGFRA 63/4885KDR 4/4885MET 3/4885
US-20070054928-A1 c-Met modulators and methods of use FLT4, FLT1, MET PDGFRA 63/4885KDR 4/4885MET 3/4885
US-20150376133-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET PDGFRA 63/4885KDR 4/4885MET 3/4885
US-20170355678-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET PDGFRA 63/4885KDR 4/4885MET 3/4885
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE FLT4, FLT1, MET PDGFRA 63/4885KDR 4/4885MET 3/4885
US-20040242603-A1 Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus proliferator receptor and medicinal composition containing the same NR1H2, NR1H3, NR1H4 PDGFRA 1364/4885KDR 1874/4885MET 72/4885
US-20080312221-A1 QUINOLINE DERIVATIVE AND QUINAZOLINE DERIVATIVE INHIBITING SELF-PHOSPHORYLATION OF HEPATOCYTUS PROLIFERATOR RECEPTOR, AND MEDICINAL COMPOSITION CONTAINING THE SAME NR1H2, NR1H3, NR1H4 PDGFRA 1825/4885KDR 3100/4885MET 320/4885
US-11124482-B2 C-met modulators and methods of use FLT4, FLT1, MET PDGFRA 63/4885KDR 4/4885MET 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.